Iterum Therapeutics plc (ITRMF) Capital Expenditures (2017 - 2025)

Iterum Therapeutics has reported Capital Expenditures for 8 years, with the latest figure at $12000.0 in Q3 2025.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $12000.0 in Q3 2025; TTM through Sep 2025 was $14000.0, a 66.67% decrease from a year earlier, with the FY2024 full-year figure at $2000.0, down 84.62% from the prior year.
• Capital Expenditures was $12000.0 for Q3 2025 at Iterum Therapeutics, up from $2000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $45000.0 in Q4 2022, with the low at -$3000.0 in Q3 2023.
• Average Capital Expenditures over 4 years is $12666.7, with a median of $9500.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 246.15% in 2022, then plunged 142.86% in 2023.
• Over 4 years, Capital Expenditures stood at $13000.0 in 2021, then surged by 246.15% to $45000.0 in 2022, then tumbled by 106.67% to -$3000.0 in 2023, then surged by 500.0% to $12000.0 in 2025.
• The last three Capital Expenditures figures came in at $12000.0 (Q3 2025), $2000.0 (Q1 2025), and -$3000.0 (Q3 2023), per Business Quant data.